Innate Pharma Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Jonathan Dickinson
Chief executive officer
€939.6k
Total compensation
| CEO salary percentage | 58.53% |
| CEO tenure | 1.6yrs |
| CEO ownership | n/a |
| Management average tenure | 2.4yrs |
| Board average tenure | 1.1yrs |
Recent management updates
Recent updates
Narrative Update • May 11
IPH: 2026 Oncology Catalysts Will Drive Reassessment Of Risk Reward Profile
Analysts have lifted their price target on Innate Pharma to €8, citing a recalibrated risk profile, a slightly lower discount rate and updated expectations around revenue growth, profit margins and future P/E in light of what they describe as a crucial catalyst stretch for the company’s oncology pipeline through 2026. Analyst Commentary Analysts highlight that the updated €8 price target is closely linked to what they describe as a tight catalyst timeline through 2026.Narrative Update • Apr 24
IPH: 2026 Oncology Readouts Will Define Upside Potential For This Catalyst Story
Narrative update overview Analysts have maintained a €4.50 price target for Innate Pharma, citing updated assumptions on discount rate, revenue, profit margins and future P/E, alongside upcoming 2026 oncology catalysts highlighted in recent Street research. Analyst Commentary Recent Street research frames Innate Pharma as a high-risk, event driven story into 2026, with attention centered on three oncology programs that analysts see as key to justifying current valuation assumptions.Narrative Update • Apr 09
IPH: Crucial 2026 Oncology Catalysts Are Expected To Unlock Long Term Upside
Analysts have trimmed their fair value estimate for Innate Pharma from about €6.10 to roughly €4.50, citing a reset in revenue growth expectations and a much higher assumed future P/E multiple, while also highlighting upcoming 2026 oncology catalysts as key to the story. Analyst Commentary Recent research has framed 2026 as an important test for Innate Pharma, with several oncology readouts and milestones clustered into what has been described as a crucial catalyst stretch.Analysis Article • Mar 29
Earnings Update: Innate Pharma S.A. (EPA:IPH) Just Reported And Analysts Are Boosting Their Estimates
Investors in Innate Pharma S.A. ( EPA:IPH ) had a good week, as its shares rose 2.4% to close at €1.10 following the...
Narrative Update • Mar 25
IPH: 2026 Oncology Catalysts Are Expected To Support Higher Future Multiple
Analysts have raised their price target on Innate Pharma to €8, citing a refreshed view of the company’s 2026 oncology catalyst lineup, including upcoming monalizumab PACIFIC-9 topline data, IPH4502 Phase 1 readout in solid tumors, and potential Phase 3 initiation for lacutamab pending financing. Analyst Commentary Recent commentary frames Innate Pharma as entering what some bullish analysts describe as a crucial catalyst stretch in 2026, with three oncology programs all lined up for key clinical events.Narrative Update • Mar 11
IPH: Higher Margin Outlook Will Support Higher Future Earnings Multiple
Analysts have adjusted their price target on Innate Pharma, reflecting updated assumptions for the company’s discount rate, revenue growth outlook and future P/E. The new target is now set at €6.10, compared with the previous €6.10.Narrative Update • Feb 25
IPH: Higher Margin Outlook Will Support Significantly Improved Future Earnings Multiple
Analysts have lifted their price target on Innate Pharma from €4.93 to €6.10, citing updated assumptions for revenue, profit margins and future P/E that together support a higher estimated fair value despite a slightly higher discount rate. Valuation Changes Fair Value: analyst estimate raised from €4.93 to €6.10, representing a sizeable upward revision in the implied share value.Narrative Update • Feb 11
IPH: Updated Assumptions For Discount Rate Will Support Long Term Upside
Analysts have kept their price target for Innate Pharma broadly in line with prior views, with only a marginal adjustment reflecting updated assumptions on the discount rate, revenue growth and future P/E, rather than any major shift in conviction. Valuation Changes Fair Value: Kept unchanged at €6.10, indicating no alteration to the central valuation estimate.Narrative Update • Jan 27
IPH: Upcoming Phase 3 CTCL Trial Will Support Long Term Upside Potential
Analysts have trimmed their price targets for Innate Pharma by a small amount, citing updated assumptions around discount rates, revenue growth, profit margins, and a lower forward P/E, which together indicate a more measured view of the company’s risk and earnings profile. What's in the News The FDA completed its review of Innate Pharma's confirmatory Phase 3 protocol for lacutamab in cutaneous T cell lymphomas, with no further comments, clearing the TELLOMAK 3 trial to proceed (Key Developments).Narrative Update • Jan 12
IPH: Regulatory Progress In Cutaneous T-Cell Lymphomas Will Drive Future Upside
Analysts have raised their price target for Innate Pharma, citing a higher fair value estimate of €6.10 per share compared with the prior €2.49. The revised estimate is supported by updated assumptions around revenue growth, profit margins, discount rate and future P/E.Analysis Article • Nov 17
Is Innate Pharma (EPA:IPH) Using Debt In A Risky Way?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Narrative Update • Sep 18
Clinical Trial Enrollment And FDA Designation Will Open Oncology Opportunities
Analysts have raised Innate Pharma’s price target to €4.93 amid a refocused pipeline and higher risk concentration on antibody-drug conjugates, while cautioning that execution challenges, financing overhang, and lack of partnerships temper near-term confidence. Analyst Commentary Bearish analysts cite Innate Pharma's decision to deprioritize its proprietary antibody-based NK cell engager platform, which they believe overly concentrates the company’s pipeline risk onto its antibody-drug conjugate strategy.Analysis Article • Jul 19
Innate Pharma S.A.'s (EPA:IPH) Popularity With Investors Is Under Threat From Overpricing
You may think that with a price-to-sales (or "P/S") ratio of 7.9x Innate Pharma S.A. ( EPA:IPH ) is a stock to avoid...
New Narrative • Apr 04
Clinical Trial Enrollment And FDA Designation Will Open Oncology Opportunities
A robust pipeline of innovative oncology therapeutics and drug candidates highlights strong R&D productivity potentially leading to substantial future earnings.Analysis Article • Apr 02
News Flash: Analysts Just Made A Notable Upgrade To Their Innate Pharma S.A. (EPA:IPH) Forecasts
Celebrations may be in order for Innate Pharma S.A. ( EPA:IPH ) shareholders, with the analysts delivering a...Analysis Article • Feb 22
Revenues Not Telling The Story For Innate Pharma S.A. (EPA:IPH) After Shares Rise 26%
Innate Pharma S.A. ( EPA:IPH ) shares have continued their recent momentum with a 26% gain in the last month alone. The...Analysis Article • Dec 20
Subdued Growth No Barrier To Innate Pharma S.A. (EPA:IPH) With Shares Advancing 37%
Innate Pharma S.A. ( EPA:IPH ) shares have had a really impressive month, gaining 37% after a shaky period beforehand...Analysis Article • Oct 24
Risks To Shareholder Returns Are Elevated At These Prices For Innate Pharma S.A. (EPA:IPH)
It's not a stretch to say that Innate Pharma S.A.'s ( EPA:IPH ) price-to-sales (or "P/S") ratio of 4.1x right now seems...Analysis Article • May 21
Benign Growth For Innate Pharma S.A. (EPA:IPH) Underpins Its Share Price
You may think that with a price-to-sales (or "P/S") ratio of 3.4x Innate Pharma S.A. ( EPA:IPH ) is definitely a stock...Analysis Article • Mar 24
Innate Pharma S.A. (EPA:IPH) Annual Results: Here's What Analysts Are Forecasting For This Year
Innate Pharma S.A. ( EPA:IPH ) just released its latest annual results and things are looking bullish. The results were...Analysis Article • Dec 21
Is Innate Pharma (EPA:IPH) Using Debt In A Risky Way?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysis Article • Sep 30
Analysts' Revenue Estimates For Innate Pharma S.A. (EPA:IPH) Are Surging Higher
Innate Pharma S.A. ( EPA:IPH ) shareholders will have a reason to smile today, with the analysts making substantial...Analysis Article • Sep 16
Some Innate Pharma S.A. (EPA:IPH) Analysts Just Made A Major Cut To Next Year's Estimates
Today is shaping up negative for Innate Pharma S.A. ( EPA:IPH ) shareholders, with the analysts delivering a...Analysis Article • Jun 09
Is Innate Pharma (EPA:IPH) Using Debt In A Risky Way?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2025 | €940k | €550k | -€49m |
| Sep 30 2025 | n/a | n/a | -€48m |
| Jun 30 2025 | n/a | n/a | -€46m |
| Mar 31 2025 | n/a | n/a | -€48m |
| Dec 31 2024 | €435k | €92k | -€49m |
Compensation vs Market: Jonathan's total compensation ($USD1.09M) is above average for companies of similar size in the French market ($USD582.09K).
Compensation vs Earnings: Jonathan's compensation has increased whilst the company is unprofitable.
CEO
Jonathan Dickinson (58 yo)
1.6yrs
Tenure
€939,625
Compensation
Mr. Jonathan E. Dickinson, MBA, BSc served as Executive Vice President and General Manager of Europe at Incyte Corp. since June 2019 until October 2024. Mr. Dickinson is Chief Executive Officer of Innate P...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.6yrs | €939.63k | no data | |
| Executive VP & COO | 2.4yrs | €163.69k | 0.40% € 603.2k | |
| Executive VP & Chief Medical Officer | 1.4yrs | €188.14k | no data | |
| Founder | no data | no data | no data | |
| Founder | no data | no data | no data | |
| Founder | no data | no data | no data | |
| Founder | no data | no data | no data | |
| Senior VP & CFO | 5.2yrs | no data | 0.080% € 121.1k | |
| Vice President of Investor Relations | 1.4yrs | no data | 0.032% € 47.7k | |
| VP, Chief of Compliance & Operations Officer and Interim Head of HR | 7.4yrs | no data | 0.15% € 219.6k | |
| VP of Legal & Corporate Affairs and Secretary of the Supervisory Board | 3.4yrs | no data | 0.054% € 81.7k |
2.4yrs
Average Tenure
53yo
Average Age
Experienced Management: IPH's management team is considered experienced (2.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.1yrs | €939.63k | no data | |
| Director | 1.1yrs | no data | no data | |
| Director | 1.1yrs | €34.00k | no data | |
| Director | 1.1yrs | €41.50k | no data | |
| Independent Director | 1.1yrs | €85.00k | 0.0027% € 4.0k | |
| Independent Chairwoman of the Board | 1.1yrs | no data | 0.027% € 40.5k | |
| Independent Vice Chairperson of the Board | 1.1yrs | €89.50k | 0.0011% € 1.6k | |
| Independent Director | 1.1yrs | €79.00k | 0.00070% € 1.1k | |
| Strategic Advisory Board Member | 2.4yrs | no data | no data | |
| Strategic Advisory Board Member | 7.6yrs | no data | no data |
1.1yrs
Average Tenure
61yo
Average Age
Experienced Board: IPH's board of directors are not considered experienced ( 1.1 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/01 17:47 |
| End of Day Share Price | 2026/06/01 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Innate Pharma S.A. is covered by 13 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Justin Zelin | BTIG |
| Suranjit Mukherjee | BTIG |
| Yigal Nochomovitz | Citigroup Inc |